How to Exclude Thrombotic Microangiopathy (TMA)
To exclude TMA, you must demonstrate the absence of both microangiopathic hemolytic anemia (MAHA) and thrombocytopenia through specific laboratory findings: normal platelet count, absence of schistocytes on blood film, normal LDH, detectable haptoglobin, and normal reticulocyte count. 1, 2
Initial Laboratory Screening
When TMA is suspected, immediately order:
Essential Tests to Exclude TMA:
- Complete blood count with platelet count - TMA typically shows platelets <30 × 10⁹/L, though higher counts don't exclude it 1, 2
- Blood film examination within 60 minutes - Look for schistocytes (red cell fragments), though these may be initially absent in up to some cases 1
- Reticulocyte count - Elevated (>120 × 10⁹/L) suggests hemolysis; low reticulocyte production index argues against TMA and toward pseudo-TMA 1, 3
- Serum haptoglobin - Undetectable in hemolysis; detectable levels help exclude TMA 1
- Lactate dehydrogenase (LDH) - Elevated in hemolysis; levels >2500 units/L suggest pseudo-TMA from B12 deficiency rather than true TMA 3
- Coagulation profile (PT/PTT, fibrinogen) - Normal in TMA; abnormal suggests DIC instead 1
- Direct antiglobulin test (DAT/Coombs) - Nearly always negative in TTP; positive suggests autoimmune hemolytic anemia 2
Critical Differentiating Features
If TMA is Present, Determine the Type:
Immediately send ADAMTS13 activity before any plasma therapy 2:
- ADAMTS13 <10% = TTP (97% sensitivity, 100% specificity) 2
- ADAMTS13 >10% = Other TMA (complement-mediated, HUS, secondary causes) 4
Key Clinical Clues That Help Exclude Specific TMAs:
Severe renal dysfunction (creatinine >2.0-2.25 mg/dL):
- Argues against TTP and toward HUS or complement-mediated TMA 2
- TTP typically shows mild-to-moderate kidney dysfunction 2
Normal coagulation parameters:
- Excludes DIC as the cause 1
Pancytopenia with low reticulocyte production index:
- Suggests pseudo-TMA from B12 deficiency, not true TMA 3
Absence of neurologic, cardiac, or renal involvement:
- Makes TMA less likely but doesn't exclude it, as 18% of TTP patients are ambulatory at diagnosis 2
Common Pitfalls to Avoid
Don't wait for schistocytes - They may be absent initially or missed on routine review 1
Don't rely solely on platelet count - Platelets ≥30 × 10⁹/L don't exclude TMA, though they make other diagnoses more likely 2
Don't assume normal ADAMTS13 excludes all TMA - It only excludes TTP; other TMAs (complement-mediated, HUS, secondary) will have ADAMTS13 >10% 4, 5
Don't miss renal-limited TMA - Can occur without systemic hematologic abnormalities; requires kidney biopsy for diagnosis 6
Don't forget pseudo-TMA from B12 deficiency - Check B12 level if LDH is exaggeratedly elevated (>2500), patient appears clinically well, and has pancytopenia with low reticulocyte count 3
Algorithmic Approach to Exclusion
Step 1: Check CBC with platelets
- Normal platelets → TMA unlikely (but check blood film anyway if anemia present)
Step 2: Examine blood film urgently
- No schistocytes + normal platelets + normal LDH + detectable haptoglobin → TMA excluded
Step 3: If thrombocytopenia and/or hemolysis present:
- Check coagulation profile → abnormal = DIC, not primary TMA
- Check DAT → positive = consider autoimmune hemolytic anemia
- Check pregnancy test in women
- Check B12 level if LDH >2500 and patient appears well
Step 4: If MAHA + thrombocytopenia confirmed:
- Send ADAMTS13 activity (before plasma therapy) 1
- Assess organ involvement (troponin, creatinine, neurologic exam) 2
- Consider kidney biopsy if no systemic features but AKI present 6
Step 5: Interpret ADAMTS13:
- <10% = TTP confirmed
10% = Consider complement-mediated TMA, HUS, or secondary causes 4
The most recent guidelines emphasize that laboratories must have documented rapid pathways for blood film examination within 60 minutes when platelets are <30 × 10⁹/L, with immediate escalation to clinical hematology if hemolysis is present 1. Access to urgent ADAMTS13 testing (turnaround 30-40 minutes with automated assays) is now standard of care 1.